Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kerry Lynn Reynolds, M.D.

Co-Author

This page shows the publications co-authored by Kerry Reynolds and Tomas Neilan.
Connection Strength

4.707
  1. Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. Eur J Cancer. 2022 Mar; 163:108-118.
    View in: PubMed
    Score: 0.245
  2. Immune checkpoint inhibitors for cancer and venous thromboembolic events. Eur J Cancer. 2021 Oct 15; 158:99-110.
    View in: PubMed
    Score: 0.241
  3. Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. 2021 09; 9(9).
    View in: PubMed
    Score: 0.239
  4. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021 07; 9(7).
    View in: PubMed
    Score: 0.236
  5. Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors. Immunother Adv. 2021 Jan; 1(1):ltab014.
    View in: PubMed
    Score: 0.236
  6. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021 06; 9(6).
    View in: PubMed
    Score: 0.235
  7. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist. 2021 06; 26(6):514-522.
    View in: PubMed
    Score: 0.232
  8. Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Coll Cardiol. 2021 03 30; 77(12):1503-1516.
    View in: PubMed
    Score: 0.232
  9. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021 03; 9(3).
    View in: PubMed
    Score: 0.231
  10. The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer. JACC CardioOncol. 2021 Mar; 3(1):35-47.
    View in: PubMed
    Score: 0.229
  11. Decreased Absolute Lymphocyte Count and Increased Neutrophil/Lymphocyte Ratio With Immune Checkpoint Inhibitor-Associated Myocarditis. J Am Heart Assoc. 2020 12; 9(23):e018306.
    View in: PubMed
    Score: 0.226
  12. Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. Circulation. 2020 12 15; 142(24):2299-2311.
    View in: PubMed
    Score: 0.224
  13. Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis. Circulation. 2020 06 16; 141(24):2031-2034.
    View in: PubMed
    Score: 0.220
  14. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020 05 07; 41(18):1733-1743.
    View in: PubMed
    Score: 0.218
  15. COVID-19 and immune checkpoint inhibitors: initial considerations. J Immunother Cancer. 2020 05; 8(1).
    View in: PubMed
    Score: 0.218
  16. Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. J Am Coll Cardiol. 2020 02 11; 75(5):467-478.
    View in: PubMed
    Score: 0.215
  17. Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2020 03; 25(3):e398-e404.
    View in: PubMed
    Score: 0.211
  18. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. J Immunother Cancer. 2019 02 22; 7(1):53.
    View in: PubMed
    Score: 0.201
  19. Reply: Immunosuppression Does Not Reduce Antitumor Efficacy. J Am Coll Cardiol. 2018 08 07; 72(6):702.
    View in: PubMed
    Score: 0.193
  20. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018 04 24; 71(16):1755-1764.
    View in: PubMed
    Score: 0.188
  21. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022 01 31; 43(4):280-299.
    View in: PubMed
    Score: 0.062
  22. Immune checkpoint inhibitor-induced thyroiditis is a risk factor for acute and chronic kidney dysfunction. Nephrol Dial Transplant. 2021 12 31; 37(1):187-189.
    View in: PubMed
    Score: 0.061
  23. Incidence and Predictors of CKD and Estimated GFR Decline in Patients Receiving Immune Checkpoint Inhibitors. Am J Kidney Dis. 2022 01; 79(1):134-137.
    View in: PubMed
    Score: 0.059
  24. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series. Am J Kidney Dis. 2020 08; 76(2):299-302.
    View in: PubMed
    Score: 0.055
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.